<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01023035</url>
  </required_header>
  <id_info>
    <org_study_id>P06086</org_study_id>
    <secondary_id>2009-012782-63</secondary_id>
    <nct_id>NCT01023035</nct_id>
  </id_info>
  <brief_title>Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM2)</brief_title>
  <official_title>Boceprevir and Peginterferon/Ribavirin for the Treatment of Chronic Hepatitis C in Treatment-Naive Subjects: A Comparison of Erythropoietin Use Versus Ribavirin Dose Reduction for the Management of Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current trial is designed to prospectively explore the safety of erythropoietin use for
      the treatment of anemia during boceprevir plus peginterferon alfa-2b/Ribavirin (PEG2b/RBV)
      therapy and to assess its relationship to efficacy. All participants in this trial will be
      treated with the triple combination of boceprevir plus PEG2b/RBV. If a participant becomes
      anemic during treatment, the participant will be randomized to one of two therapeutic
      strategies for management of anemia (erythropoietin use versus RBV dose reduction).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Sustained Virologic Response (SVR)</measure>
    <time_frame>At Follow-up Week 24</time_frame>
    <description>SVR was defined as undetectable plasma Hepatitis C Virus ribonucleic acid (HCV-RNA) at Follow-up Week 24</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Discontinued Treatment</measure>
    <time_frame>From Study Day 1 up to Study Treatment Week 48</time_frame>
    <description>Cumulative discontinuation was defined as the sum of discontinuations due to adverse events, viral breakthrough/resistance, detectable HCV-RNA and futility rules (&lt;2-log10 decline in HCV-RNA at Treatment Week 12, ≥ Lower Limit of Quantification [LLQ] HCV-RNA at Treatment Week 24), and other (noncompliance, withdrawal of consent, lost to follow-up).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">687</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>Treated/Not Randomized</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 4 weeks of PEG2b/RBV followed by 24 or 44 weeks of boceprevir plus PEG2b/RBV depending on Hepatitis C Virus RNA (HCV-RNA) levels. Participants continued with this treatment if their serum hemoglobin remained &gt;10 g/dL throughout the 28- or 48-week treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ribavirin Dose Reduction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After the initiation of treatment with 4 weeks with PEG2b/RBV followed by 24 or 44 weeks of boceprevir, participants who became anemic (serum hemoglobin = ≤10 g/dL) within the 28- or 48-week treatment period and who were randomized to the Ribavirin (RBV) Dose Reduction Arm received reduced doses of RBV for management of the anemia in combination with PEG2b and boceprevir therapies.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Erythropoietin Use</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After the initiation of treatment with 4 weeks with PEG2b/RBV followed by 24 or 44 weeks of boceprevir, participants who became anemic (serum hemoglobin = ≤10 g/dL) within the 28- or 48-week treatment period and who were randomized to the Erythropoietin Use Arm received erythropoietin for management of the anemia in addition to PEG2b/RBV and boceprevir therapies.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Boceprevir</intervention_name>
    <description>800 mg given three times a day (TID), orally (PO)</description>
    <arm_group_label>Treated/Not Randomized</arm_group_label>
    <arm_group_label>Ribavirin Dose Reduction</arm_group_label>
    <arm_group_label>Erythropoietin Use</arm_group_label>
    <other_name>SCH 503034</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa-2b (PEG2b)</intervention_name>
    <description>1.5 µg/kg/week given subcutaneously (SC)</description>
    <arm_group_label>Treated/Not Randomized</arm_group_label>
    <arm_group_label>Ribavirin Dose Reduction</arm_group_label>
    <arm_group_label>Erythropoietin Use</arm_group_label>
    <other_name>SCH 054031</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin (RBV)</intervention_name>
    <description>Ribavirin weight-based dosing (WBD), 600 to 1400 mg/day given twice daily (BID), orally (PO)</description>
    <arm_group_label>Treated/Not Randomized</arm_group_label>
    <arm_group_label>Ribavirin Dose Reduction</arm_group_label>
    <arm_group_label>Erythropoietin Use</arm_group_label>
    <other_name>SCH 018908, Rebetol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythropoietin</intervention_name>
    <description>Initial dose of 40,000 Units given subcutaneously (SC) once weekly (QW), with dose adjustment as necessary to achieve and maintain serum hemoglobin levels of 10-12 g/dL</description>
    <arm_group_label>Erythropoietin Use</arm_group_label>
    <other_name>Procrit, Eprex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant must have previously documented Chronic Hepatitis C (CHC) genotype 1
             infection.

          -  Hemoglobin concentration at Screening must be ≤15 g/dL for both females and males.

          -  Participant must have a liver biopsy with histology consistent with CHC and no other
             etiology.

          -  Participant with bridging fibrosis (F3) or cirrhosis (F4) must have an ultrasound
             within 6 months of the Screening Visit (or between Screening and Day 1) with no
             findings suspicious for hepatocellular carcinoma.

          -  Participant's weight must be ≥40 kg and ≤125 kg.

          -  Participant and participant's partner(s) must each agree to use acceptable methods of
             contraception for at least 2 weeks prior to Day 1 and continue until at least 6 months
             after last dose of study medication, or longer if dictated by local regulations.

          -  Participant must be willing to give written informed consent.

          -  Participant must be willing to attend frequent site visits for the duration of the
             trial.

          -  Participant must not have any contraindications for the use of erythropoietin.

        Exclusion Criteria:

          -  Participants known to be coinfected with the human immunodeficiency virus (HIV) or
             hepatitis B virus.

          -  Participants who received prior treatment for hepatitis C.

          -  Treatment with any investigational drug within 30 days of the screening visit in this
             trial.

          -  Participants receiving any of the following medication(s) within 2 weeks prior to the
             Day 1 visit: alfuzosin, antiarrhythmics (amiodarone, bepridil, flecainide,
             propafenone, and quinidine), ergot derivatives, cisapride, lovastatin, simvastatin,
             pimozide, triazolam, and orally administered midazolam.

          -  Participation in any other clinical trial within 30 days of the screening visit in
             this trial or intention to participate in another clinical trial during participation
             in this trial.

          -  Evidence of decompensated liver disease.

          -  Diabetic and/or hypertensive participants with clinically significant ocular
             examination findings.

          -  Pre-existing psychiatric condition(s).

          -  Clinical diagnosis of substance abuse of specified drugs within specified timeframes.

          -  Any known pre-existing medical condition that could interfere with the participant's
             participation in and completion of the trial.

          -  Evidence of active or suspected malignancy, or a history of malignancy, within the
             last 5 years (except adequately treated carcinoma in situ and basal cell carcinoma of
             the skin).

          -  Participants who are pregnant or nursing. Participants who intend to become pregnant
             during the trial period. Male participants with partners who are, or intend to become,
             pregnant during the trial period.

          -  Any other condition which, in the opinion of a physician, would make the participant
             unsuitable for enrollment or could interfere with the participant participating in and
             completing the trial.

          -  Participant who had a life-threatening serious adverse event during the screening
             period.

          -  A participant must not be a member or a family member of the personnel of the
             investigational or sponsor staff directly involved with this trial.

          -  Protocol-specified hematologic, biochemical, and serologic criteria (growth factors
             may not be used to achieve trial entry requirements).

          -  Serum albumin below the lower limit of normal (LLN) of laboratory reference range.

          -  Thyroid-stimulating hormone (TSH) &gt;1.2 x Upper Limit of Normal (ULN) or &lt;0.8 x LLN of
             laboratory reference.

          -  Serum creatinine &gt;ULN of the laboratory reference.

          -  Protocol-specified serum glucose concentrations.

          -  Prothrombin time/partial thromboplastin time (PT/PTT) values &gt;10% above laboratory
             reference range.

          -  Protocol-specified alpha fetoprotein concentrations.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2009</study_first_submitted>
  <study_first_submitted_qc>November 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2009</study_first_posted>
  <results_first_submitted>October 16, 2012</results_first_submitted>
  <results_first_submitted_qc>October 16, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 15, 2012</results_first_posted>
  <last_update_submitted>March 9, 2017</last_update_submitted>
  <last_update_submitted_qc>March 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>687 Participants enrolled and were treated with Peginterferon/Ribavirin (PEG2b/RBV) followed by PEG2b/RBV + boceprevir. 500 participants became anemic during treatment and were randomized to either the RBV Dose Reduction Arm (n=249) or the Erythropoietin Use Arm (n=251).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ribavirin Dose Reduction Arm</title>
          <description>After the initiation of treatment with 4 weeks with PEG2b/RBV followed by 24 or 44 weeks of boceprevir, participants who became anemic (serum hemoglobin = ≤10 g/dL) within the 28- or 48-week treatment period and who were randomized to the Ribavirin (RBV) Dose Reduction Arm received reduced doses of RBV for management of the anemia in combination with PEG2b and boceprevir therapies.</description>
        </group>
        <group group_id="P2">
          <title>Erythropoietin Use Arm</title>
          <description>After the initiation of treatment with 4 weeks with PEG2b/RBV followed by 24 or 44 weeks of boceprevir, participants who became anemic (serum hemoglobin = ≤10 g/dL) within the 28- or 48-week treatment period and who were randomized to the Erythropoietin Use Arm received erythropoietin for management of the anemia in addition to PEG2b/RBV and boceprevir therapies.</description>
        </group>
        <group group_id="P3">
          <title>Treated/Not Randomized</title>
          <description>Participants received 4 weeks of PEG2b/RBV followed by 24 or 44 weeks of boceprevir plus PEG2b/RBV depending on Hepatitis C Virus RNA (HCV-RNA) levels. Participants continued with this treatment if their serum hemoglobin remained &gt;10 g/dL throughout the 28- or 48-week treatment period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="249"/>
                <participants group_id="P2" count="251"/>
                <participants group_id="P3" count="187"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="177"/>
                <participants group_id="P2" count="166"/>
                <participants group_id="P3" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
                <participants group_id="P2" count="85"/>
                <participants group_id="P3" count="118"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="50"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Medical Reasons</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="44"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment Failure</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow-up Period (up to Week 72)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="238"/>
                <participants group_id="P2" count="235"/>
                <participants group_id="P3" count="147"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="210"/>
                <participants group_id="P2" count="207"/>
                <participants group_id="P3" count="108"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="39"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-medical Reason</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="38"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ribavirin Dose Reduction Arm</title>
          <description>After the initiation of treatment with 4 weeks with PEG2b/RBV followed by 24 or 44 weeks of boceprevir, participants who became anemic (serum hemoglobin = ≤10 g/dL) within the 28- or 48-week treatment period and who were randomized to the Ribavirin (RBV) Dose Reduction Arm received reduced doses of RBV for management of the anemia in combination with PEG2b and boceprevir therapies.</description>
        </group>
        <group group_id="B2">
          <title>Erythropoietin Use Arm</title>
          <description>After the initiation of treatment with 4 weeks with PEG2b/RBV followed by 24 or 44 weeks of boceprevir, participants who became anemic (serum hemoglobin = ≤10 g/dL) within the 28- or 48-week treatment period and who were randomized to the Erythropoietin Use Arm received erythropoietin for management of the anemia in addition to PEG2b/RBV and boceprevir therapies.</description>
        </group>
        <group group_id="B3">
          <title>Treated/Not Randomized</title>
          <description>Participants received 4 weeks of PEG2b/RBV followed by 24 or 44 weeks of boceprevir plus PEG2b/RBV depending on Hepatitis C Virus RNA (HCV-RNA) levels. Participants continued with this treatment if their serum hemoglobin remained &gt;10 g/dL throughout the 28- or 48-week treatment period.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="249"/>
            <count group_id="B2" value="251"/>
            <count group_id="B3" value="187"/>
            <count group_id="B4" value="687"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.2" spread="9.9"/>
                    <measurement group_id="B2" value="49.7" spread="9.7"/>
                    <measurement group_id="B3" value="47.5" spread="10.1"/>
                    <measurement group_id="B4" value="49.3" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="171"/>
                    <measurement group_id="B2" value="164"/>
                    <measurement group_id="B3" value="99"/>
                    <measurement group_id="B4" value="434"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="88"/>
                    <measurement group_id="B4" value="253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Sustained Virologic Response (SVR)</title>
        <description>SVR was defined as undetectable plasma Hepatitis C Virus ribonucleic acid (HCV-RNA) at Follow-up Week 24</description>
        <time_frame>At Follow-up Week 24</time_frame>
        <population>The primary efficacy analysis was performed on all participants who were randomized to either the RBV Dose Reduction Arm or the EPO Use Arm for anemia management (i.e. the Full Analysis Set of patients requiring anemia management [FAS, n=500]).</population>
        <group_list>
          <group group_id="O1">
            <title>Ribavirin Dose Reduction Arm</title>
            <description>After treatment for 4 weeks with PEG2b/RBV followed by 24 or 44 weeks of boceprevir, participants who became anemic (serum hemoglobin of ≤10 g/dL) within the 28- or 48-week treatment period and who were randomized to the Ribavirin (RBV) Dose Reduction Arm received reduced doses of RBV for management of the anemia in combination with PEG2b and boceprevir therapies.</description>
          </group>
          <group group_id="O2">
            <title>Erythropoietin Use Arm</title>
            <description>After treatment for 4 weeks with PEG2b/RBV followed by 24 or 44 weeks of boceprevir, participants who became anemic (serum hemoglobin of ≤10 g/dL) within the 28- or 48-week treatment period and who were randomized to the Erythropoietin Use Arm received erythropoietin for management of the anemia in addition to PEG2b/RBV and boceprevir therapies.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Sustained Virologic Response (SVR)</title>
          <description>SVR was defined as undetectable plasma Hepatitis C Virus ribonucleic acid (HCV-RNA) at Follow-up Week 24</description>
          <population>The primary efficacy analysis was performed on all participants who were randomized to either the RBV Dose Reduction Arm or the EPO Use Arm for anemia management (i.e. the Full Analysis Set of patients requiring anemia management [FAS, n=500]).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.5"/>
                    <measurement group_id="O2" value="70.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The modified Koch method was used to calculate the stratum-adjusted Mantel-Haenszel (MH) difference between the SVR rates for the Erythropoietin Use Arm versus the Ribavirin Dose Reduction Arm and corresponding 95% confidence interval with continuity correction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.6</ci_lower_limit>
            <ci_upper_limit>7.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Discontinued Treatment</title>
        <description>Cumulative discontinuation was defined as the sum of discontinuations due to adverse events, viral breakthrough/resistance, detectable HCV-RNA and futility rules (&lt;2-log10 decline in HCV-RNA at Treatment Week 12, ≥ Lower Limit of Quantification [LLQ] HCV-RNA at Treatment Week 24), and other (noncompliance, withdrawal of consent, lost to follow-up).</description>
        <time_frame>From Study Day 1 up to Study Treatment Week 48</time_frame>
        <population>All Treated Participants, defined as all participants who were treated with any study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Ribavirin Dose Reduction Arm</title>
            <description>After treatment for 4 weeks with PEG2b/RBV followed by 24 or 44 weeks of boceprevir, participants who became anemic (serum hemoglobin = ≤10 g/dL) within the 28- or 48-week treatment period and who were randomized to the Ribavirin (RBV) Dose Reduction Arm received reduced doses of RBV for management of the anemia in combination with PEG2b and boceprevir therapies.</description>
          </group>
          <group group_id="O2">
            <title>Erythropoietin Use Arm</title>
            <description>After treatment for 4 weeks with PEG2b/RBV followed by 24 or 44 weeks of boceprevir, participants who became anemic (serum hemoglobin = ≤10 g/dL) within the 28- or 48-week treatment period and who were randomized to the Erythropoietin Use Arm received erythropoietin for management of the anemia in addition to PEG2b/RBV and boceprevir therapies.</description>
          </group>
          <group group_id="O3">
            <title>Treated/Not Randomized</title>
            <description>Participants received 4 weeks of PEG2b/RBV followed by 24 or 44 weeks of boceprevir plus PEG2b/RBV depending on Hepatitis C Virus RNA (HCV-RNA) levels. Participants continued with this treatment if their serum hemoglobin remained &gt;10 g/dL throughout the 28- or 48-week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Discontinued Treatment</title>
          <description>Cumulative discontinuation was defined as the sum of discontinuations due to adverse events, viral breakthrough/resistance, detectable HCV-RNA and futility rules (&lt;2-log10 decline in HCV-RNA at Treatment Week 12, ≥ Lower Limit of Quantification [LLQ] HCV-RNA at Treatment Week 24), and other (noncompliance, withdrawal of consent, lost to follow-up).</description>
          <population>All Treated Participants, defined as all participants who were treated with any study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="251"/>
                <count group_id="O3" value="187"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" lower_limit="23" upper_limit="35"/>
                    <measurement group_id="O2" value="34" lower_limit="28" upper_limit="40"/>
                    <measurement group_id="O3" value="63" lower_limit="56" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ribavirin Dose Reduction Arm</title>
          <description>After the initiation of treatment with 4 weeks with PEG2b/RBV followed by 24 or 44 weeks of boceprevir, participants who became anemic (serum hemoglobin = ≤10 g/dL) within the 28- or 48-week treatment period and who were randomized to the Ribavirin (RBV) Dose Reduction Arm received reduced doses of RBV for management of the anemia in combination with PEG2b and boceprevir therapies.</description>
        </group>
        <group group_id="E2">
          <title>Erythropoietin Use Arm</title>
          <description>After the initiation of treatment with 4 weeks with PEG2b/RBV followed by 24 or 44 weeks of boceprevir, participants who became anemic (serum hemoglobin = ≤10 g/dL) within the 28- or 48-week treatment period and who were randomized to the Erythropoietin Use Arm received erythropoietin for management of the anemia in addition to PEG2b/RBV and boceprevir therapies.</description>
        </group>
        <group group_id="E3">
          <title>Treated/Not Randomized</title>
          <description>Participants received 4 weeks of PEG2b/RBV followed by 24 or 44 weeks of boceprevir plus PEG2b/RBV depending on Hepatitis C Virus RNA (HCV-RNA) levels. Participants continued with this treatment if their serum hemoglobin remained &gt;10 g/dL throughout the 28- or 48-week treatment period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="249"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="251"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Pericardial Effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Sinus Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Supraventricular Tachyarrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo Positional</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal Detachment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abominal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Anal Fissure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal Reflux Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Lower Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Megacolon</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Rectal Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Upper Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="251"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="251"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Sudden Cardiac Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Cholelithiasis Obstructive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess Soft Tissue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Clostridium Difficile Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Corneal Abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Infected Skin Ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Kidney Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Tubo-ovarian Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental Overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Ankle Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Fibula Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Multiple Drug Overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Operative Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Post Procedural Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Snake Bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Traumatic Liver Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Potassium Decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Neutrophil Count Decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="249"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Diabetes Melllitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthraliga</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Anal Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Basal Cell Carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Metastases to Lymph Nodes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Pancreatic Carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Pancreatic Neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Renal Cell Carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Ischaemic Stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Toxic Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Transient Ischemic Attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>VIIth Nerve Paralysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Psychotic Disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Suicidal Behaviour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Suicide Attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Renal Colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adnexa Uteri Mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial Occlusive Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Orthostatic Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis Superficial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Thrombosed Varicose Vein</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="247" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="248" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="180" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="239" subjects_affected="172" subjects_at_risk="249"/>
                <counts group_id="E2" events="215" subjects_affected="152" subjects_at_risk="251"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="29" subjects_affected="18" subjects_at_risk="249"/>
                <counts group_id="E2" events="54" subjects_affected="21" subjects_at_risk="251"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="154" subjects_affected="71" subjects_at_risk="249"/>
                <counts group_id="E2" events="162" subjects_affected="81" subjects_at_risk="251"/>
                <counts group_id="E3" events="49" subjects_affected="30" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="249"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="251"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision Blurred</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="249"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="251"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="23" subjects_affected="20" subjects_at_risk="249"/>
                <counts group_id="E2" events="18" subjects_affected="16" subjects_at_risk="251"/>
                <counts group_id="E3" events="15" subjects_affected="10" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="249"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="251"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="249"/>
                <counts group_id="E2" events="23" subjects_affected="22" subjects_at_risk="251"/>
                <counts group_id="E3" events="15" subjects_affected="14" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="102" subjects_affected="77" subjects_at_risk="249"/>
                <counts group_id="E2" events="107" subjects_affected="87" subjects_at_risk="251"/>
                <counts group_id="E3" events="70" subjects_affected="52" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="249"/>
                <counts group_id="E2" events="30" subjects_affected="30" subjects_at_risk="251"/>
                <counts group_id="E3" events="17" subjects_affected="17" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Dysguesia</sub_title>
                <counts group_id="E1" events="94" subjects_affected="85" subjects_at_risk="249"/>
                <counts group_id="E2" events="104" subjects_affected="100" subjects_at_risk="251"/>
                <counts group_id="E3" events="67" subjects_affected="61" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="249"/>
                <counts group_id="E2" events="33" subjects_affected="24" subjects_at_risk="251"/>
                <counts group_id="E3" events="11" subjects_affected="9" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal Reflux Disease</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="249"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="251"/>
                <counts group_id="E3" events="16" subjects_affected="14" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Mouth Ulceration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="249"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="251"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="171" subjects_affected="127" subjects_at_risk="249"/>
                <counts group_id="E2" events="211" subjects_affected="153" subjects_at_risk="251"/>
                <counts group_id="E3" events="118" subjects_affected="94" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="249"/>
                <counts group_id="E2" events="22" subjects_affected="20" subjects_at_risk="251"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="66" subjects_affected="49" subjects_at_risk="249"/>
                <counts group_id="E2" events="103" subjects_affected="62" subjects_at_risk="251"/>
                <counts group_id="E3" events="48" subjects_affected="38" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="32" subjects_affected="21" subjects_at_risk="249"/>
                <counts group_id="E2" events="29" subjects_affected="19" subjects_at_risk="251"/>
                <counts group_id="E3" events="22" subjects_affected="16" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="78" subjects_affected="72" subjects_at_risk="249"/>
                <counts group_id="E2" events="86" subjects_affected="79" subjects_at_risk="251"/>
                <counts group_id="E3" events="54" subjects_affected="49" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="237" subjects_affected="174" subjects_at_risk="249"/>
                <counts group_id="E2" events="248" subjects_affected="178" subjects_at_risk="251"/>
                <counts group_id="E3" events="138" subjects_affected="108" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Influenza Like Illness</sub_title>
                <counts group_id="E1" events="74" subjects_affected="68" subjects_at_risk="249"/>
                <counts group_id="E2" events="75" subjects_affected="67" subjects_at_risk="251"/>
                <counts group_id="E3" events="47" subjects_affected="44" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Injection Site Erythema</sub_title>
                <counts group_id="E1" events="28" subjects_affected="27" subjects_at_risk="249"/>
                <counts group_id="E2" events="37" subjects_affected="33" subjects_at_risk="251"/>
                <counts group_id="E3" events="21" subjects_affected="21" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Injection Site Reaction</sub_title>
                <counts group_id="E1" events="25" subjects_affected="23" subjects_at_risk="249"/>
                <counts group_id="E2" events="36" subjects_affected="36" subjects_at_risk="251"/>
                <counts group_id="E3" events="25" subjects_affected="21" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="62" subjects_affected="51" subjects_at_risk="249"/>
                <counts group_id="E2" events="74" subjects_affected="64" subjects_at_risk="251"/>
                <counts group_id="E3" events="44" subjects_affected="41" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="249"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="251"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="21" subjects_affected="19" subjects_at_risk="249"/>
                <counts group_id="E2" events="43" subjects_affected="37" subjects_at_risk="251"/>
                <counts group_id="E3" events="22" subjects_affected="21" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="63" subjects_affected="55" subjects_at_risk="249"/>
                <counts group_id="E2" events="114" subjects_affected="70" subjects_at_risk="251"/>
                <counts group_id="E3" events="52" subjects_affected="45" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="249"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="251"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="249"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="251"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="22" subjects_affected="14" subjects_at_risk="249"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="251"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight Decreased</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="249"/>
                <counts group_id="E2" events="53" subjects_affected="39" subjects_at_risk="251"/>
                <counts group_id="E3" events="26" subjects_affected="22" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" events="65" subjects_affected="61" subjects_at_risk="249"/>
                <counts group_id="E2" events="71" subjects_affected="65" subjects_at_risk="251"/>
                <counts group_id="E3" events="56" subjects_affected="51" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="55" subjects_affected="49" subjects_at_risk="249"/>
                <counts group_id="E2" events="68" subjects_affected="58" subjects_at_risk="251"/>
                <counts group_id="E3" events="41" subjects_affected="34" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="33" subjects_affected="31" subjects_at_risk="249"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="251"/>
                <counts group_id="E3" events="19" subjects_affected="15" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="249"/>
                <counts group_id="E2" events="16" subjects_affected="12" subjects_at_risk="251"/>
                <counts group_id="E3" events="13" subjects_affected="11" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="64" subjects_affected="56" subjects_at_risk="249"/>
                <counts group_id="E2" events="66" subjects_affected="60" subjects_at_risk="251"/>
                <counts group_id="E3" events="36" subjects_affected="28" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="249"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="251"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Disturbance in Attention</sub_title>
                <counts group_id="E1" events="23" subjects_affected="21" subjects_at_risk="249"/>
                <counts group_id="E2" events="46" subjects_affected="42" subjects_at_risk="251"/>
                <counts group_id="E3" events="24" subjects_affected="20" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="70" subjects_affected="58" subjects_at_risk="249"/>
                <counts group_id="E2" events="85" subjects_affected="67" subjects_at_risk="251"/>
                <counts group_id="E3" events="38" subjects_affected="37" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="151" subjects_affected="119" subjects_at_risk="249"/>
                <counts group_id="E2" events="168" subjects_affected="136" subjects_at_risk="251"/>
                <counts group_id="E3" events="92" subjects_affected="77" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="14" subjects_at_risk="249"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="251"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="249"/>
                <counts group_id="E2" events="17" subjects_affected="14" subjects_at_risk="251"/>
                <counts group_id="E3" events="15" subjects_affected="11" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Affect Lability</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="249"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="251"/>
                <counts group_id="E3" events="11" subjects_affected="9" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="33" subjects_affected="29" subjects_at_risk="249"/>
                <counts group_id="E2" events="36" subjects_affected="30" subjects_at_risk="251"/>
                <counts group_id="E3" events="31" subjects_affected="28" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="60" subjects_affected="50" subjects_at_risk="249"/>
                <counts group_id="E2" events="65" subjects_affected="52" subjects_at_risk="251"/>
                <counts group_id="E3" events="41" subjects_affected="38" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="81" subjects_affected="72" subjects_at_risk="249"/>
                <counts group_id="E2" events="89" subjects_affected="75" subjects_at_risk="251"/>
                <counts group_id="E3" events="63" subjects_affected="60" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="65" subjects_affected="57" subjects_at_risk="249"/>
                <counts group_id="E2" events="71" subjects_affected="61" subjects_at_risk="251"/>
                <counts group_id="E3" events="42" subjects_affected="32" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="55" subjects_affected="48" subjects_at_risk="249"/>
                <counts group_id="E2" events="60" subjects_affected="52" subjects_at_risk="251"/>
                <counts group_id="E3" events="30" subjects_affected="26" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Dyspnoea Exertional</sub_title>
                <counts group_id="E1" events="32" subjects_affected="26" subjects_at_risk="249"/>
                <counts group_id="E2" events="35" subjects_affected="29" subjects_at_risk="251"/>
                <counts group_id="E3" events="20" subjects_affected="16" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" events="21" subjects_affected="16" subjects_at_risk="249"/>
                <counts group_id="E2" events="31" subjects_affected="26" subjects_at_risk="251"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Productive Cough</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="249"/>
                <counts group_id="E2" events="21" subjects_affected="17" subjects_at_risk="251"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="102" subjects_affected="95" subjects_at_risk="249"/>
                <counts group_id="E2" events="108" subjects_affected="99" subjects_at_risk="251"/>
                <counts group_id="E3" events="57" subjects_affected="55" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" events="47" subjects_affected="45" subjects_at_risk="249"/>
                <counts group_id="E2" events="45" subjects_affected="44" subjects_at_risk="251"/>
                <counts group_id="E3" events="22" subjects_affected="21" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" events="56" subjects_affected="44" subjects_at_risk="249"/>
                <counts group_id="E2" events="68" subjects_affected="57" subjects_at_risk="251"/>
                <counts group_id="E3" events="31" subjects_affected="21" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="94" subjects_affected="70" subjects_at_risk="249"/>
                <counts group_id="E2" events="100" subjects_affected="61" subjects_at_risk="251"/>
                <counts group_id="E3" events="40" subjects_affected="34" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Rash Generalised</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="249"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="251"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator agrees not to publish or publicly present any interim results of the trial without the prior written consent of the sponsor. The investigator further agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial. The sponsor shall have the right to review and comment with respect to publications, abstracts, slides, and manuscripts.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

